Option chain shows key data for Black Swan Graphene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Black Swan Graphene.

Black Swan Graphene (OTC:BSWGD) Stock, Option Chain

Black Swan Graphene Inc is focused on the large-scale production and commercialization of patented high-performance and low-cost graphene products aimed at several industrial sectors, including concrete, polymers, Li-ion batteries, and others, which are expected to require large volumes of graphene and, in turn, require large volumes of graphite.

BLACK SWAN GRAPHENE NEW by Black Swan Graphene Inc.

Black Swan Graphene Inc

WIIM

VTRS

Viatris shares are trading lower after the company reported Q4 EPS and sales below estimates, and issued FY25 revenue and EPS guidance below estimates.

Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.78) by 12.82 percent. This is a 252 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $7.39 million which missed the analyst consensus estimate of $11.82 million by 37.45 percent. This is a 84.56 percent decrease over sales of $47.88 million the same period last year.

Earnings

Earnings Misses

News

KYMR

Kymera Therapeutics Q4 2024 GAAP EPS $(0.88) Misses $(0.78) Estimate, Sales $7.39M Miss $11.82M Estimate

Warner Bros. Discovery Q4 2024 GAAP EPS $(0.20) May Not Compare To $0.05 Estimate, Sales $10.03B Miss $10.19B Estimate

Barclays analyst Brendan Lynch upgrades Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) from Equal-Weight to Overweight and raises the price target from $42 to $44.

Upgrades

Price Target

Analyst Ratings

Barclays Upgrades Kilroy Realty to Overweight, Raises Price Target to $44

Kimbell Royalty Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $0.15 by 420 percent. This is a 442.86 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $66.72 million which missed the analyst consensus estimate of $77.46 million by 13.87 percent. This is a 32.74 percent decrease over sales of $99.20 million the same period last year.

Kimbell Royalty Partners Q4 2024 GAAP EPS $(0.48) Misses $0.15 Estimate, Sales $66.72M Miss $77.46M Estimate

Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.37 by 5.41 percent. This is a 29.63 percent increase over earnings of $0.27 per share from the same period last year.

EVRG

Evergy Q4 2024 Adj EPS $0.35 Misses $0.37 Estimate

Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 8.7 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $290.20 million which missed the analyst consensus estimate of $290.88 million by 0.23 percent. This is a 6.46 percent decrease over sales of $310.24 million the same period last year.

Earnings Beats

Sotera Health Q4 Adj EPS $0.21 Beats $0.20 Estimate, Sales $290.20M Miss $290.88M Estimate

RILY

B. Riley Financial shares are trading higher after the company announced a new $160 million senior secured debt facility provided by funds managed by Oaktree Capital Management.

B. Riley Financial Enters New $160M Senior Secured Debt Facility Provided By Funds Managed By Oaktree Capital Management

Biotech

Health Care

General

SAVA

Cassava Sciences Entered Into An Agreement With Yale University For A License To Intellectual Property Rights, Including An Exclusive License To An Issued US Method Of Treatment Patent For Simufilam As A Potential Treatment For Seizures Related To Rare Neurodevelopmental Disorders

Tile Shop Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTSH#NASDAQ">TTSH</a>) reported quarterly losses of $(0.01) per share. This is a 200 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $79.45 million in sales this quarter. This is a 5.92 percent decrease over sales of $84.46 million the same period last year.

TTSH

Tile Shop Holdings Q4 EPS $(0.01) Down From $0.01 YoY, Sales $79.45M Down From $84.46M YoY

OPRA

Opera Q4 2024 Adj. EPS $0.28, Inline, Sales $145.833M Beat $137.856M Estimate

Vistra Q4 Net Income $490M, Adj. EBITDA $1.985B

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072232/Airdocw.png" alt="" class="wp-image-6721" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072232/Airdocw.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072232/Airdocw-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072232/Airdocw-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Riding on the DeepSeek frenzy, medical imaging provider Airdoc Tech has found favor with investors again after revamping its AI model, but will the recovery be short-lived?
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Shares in Airdoc Tech jumped to an eight-month high after the company announced that its upgraded AI system had been integrated with DeepSeek's model</li>
<li>The medical diagnostics company has been mired in net losses for five straight years, despite rising revenues</li>
</ul>
The unexpected arrival of DeepSeek on the global tech scene this year has set off a rapid chain reaction, as Chinese companies scramble to lock into the economical AI model as a tool for everything from chip-making to medical services.
In particular, the health technology sector was jolted out of a long stock market hibernation, as investors woke up to the potential benefits that cheaper AI could bring.
Riding the wave of enthusiasm, imaging provider&nbsp;Beijing Airdoc Technology Co.&nbsp;Ltd.&nbsp;(2251.HK)&nbsp;<a href="https://longportapp.com/en/news/227702267">announced</a>&nbsp;on Feb. 7 it had carried out an upgrade of its self-developed medical AI model to integrate the system with DeepSeek's technology.
Airdoc Tech's share price leapt 21% to an eight-month high in the 10 days after the news, buoyed by the optimism surrounding the DeepSeek breakthrough, which has shaken the foundations of the global tech industry.
Founded in 2015, Airdoc Tech specializes in diagnostic imaging tools for eye problems such as short-sightedness or vision loss caused by diabetes. Its signature product, Airdoc-AIFUNDUS, has gained a profile in the medical industry as an AI-enabled healthcare solution.
Since unveiling its own AI system, the Wanyu Medical Large Model, last July, Airdoc Tech has been trying to extend the system's reach from image-based diagnosis to general medical Q&amp;A and health management.
The Wanyu model can provide doctors with swift access to medical information, clinical guidelines and research results to inform decision-making, according to Airdoc Tech, while offering patients personalized health analysis and treatment recommendations. The upgrade announced this month has improved the speed of data processing and the accuracy of disease recognition, as well as providing a more personalized health management experience, the company said.
However, it is hard to judge the medical benefits of the revamped model as the Airdoc Tech website does not give any information on its use by medical partners to go with the publicity images.
The field of AI-powered medical services is fiercely competitive, and complex. A research report from CITIC Securities found that Chinese companies had launched more than 50 AI models for medical use. The diagnostics arena alone contains models from many big tech names, such as Tencent's Hunyuan, Baidu's Lingyi, Alibaba's Tongyi Renxin, and JD's Jingyi Qianxun.
The tools cover many medical scenarios from pre-diagnosis to follow-up care, including AI-enhanced analysis of medical images and decision-making for clinicians. Specialized tools can be easier to apply than those with a wide scope, as illustrated by the We Doctor system for managing chronic diseases and the post-diagnosis system from&nbsp;Xunfei Healthcare&nbsp;(2506.HK). In contrast, the commercial pathway for Airdoc Tech's Wanyu is less clear-cut, if the software aims to serve both doctors and patients across a range of services.
In fact, the Wanyu model is not Airdoc Tech's first foray into AI-assisted diagnosis. Two years ago, the company launched AI-powered products to prevent or control myopia.
The company's financial report for the first half of 2024 said service users had reached 16,000, with more than 800 hospitals across China using its vision training tools. However, Airdoc Tech did not disclose the specific revenue generated from the new business. It merely stated that revenues from its overall eye health business rose 22% in the six months to 38 million yuan ($5.24 million) from the year-earlier period. Sales of the tool have stalled since China reclassified it last July as a Class Three medical device, requiring stricter controls on its use. The company is in the process of applying for the necessary certifications to reboot sales.
<h4 class="wp-block-heading">Caught in a vicious cycle</h4>
Airdoc Tech was priced at a lofty HK$75.1 per share when it went public on the Hong Kong stock market in November 2021. But the price has gone downhill from there, shedding more than 80% of its value to hover around HK$10 for a long time. The constant stream of red ink has been a focus of investor concern.
Between 2019 and 2023 the company made cumulative losses of 623 million yuan. Revenue rose 13.6% to 93.71 million yuan in the first half of 2024, but the net loss doubled to 81.49 million yuan. The medical device provider appears to be trapped in a cycle of rising topline revenue coupled with a weak bottom line.
Taking a closer look at the company's&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0828/2024082802215.pdf">financial data</a>, the cost structure appears out of balance for a tech company that should typically have a big R&amp;D budget. In fact, R&amp;D expenses fell around 13% to 49 million yuan in the first half of 2024, but sales and administrative expenses came in much higher, at 80.19 million yuan. On top of that, wage costs for 254 staff amounted to whopping 103 million yuan, exceeding revenue in the same period.
Airdoc Tech may have to boost R&amp;D spending if it hopes to make a breakthrough in the business of large medical AI models. However, that could be a stretch, as the company's cash and cash equivalents had dropped to 548 million yuan by mid-2024.
Airdoc Tech's price-to-sales (P/S) ratio stands at only 7 times, in contrast to the 36 times for Xunfei Healthcare Technology, an expert in AI-powered tools for medical use. Although AI has the power to reshape the medical services business, it is hard to realize that potential in the form of commercial profits. It will take time to verify whether Airdoc Tech can grab a significant share of the medical model market.

Asia

Equities

Global

Will The DeepSeek-Frenzy Aided Recovery Last For Airdoc Technology Stock?

2025 Financial Guidance
Ligand is reaffirming the 2025 financial guidance introduced at its Investor Day on December 10, 2024. The Company continues to expect 2025 royalty revenue ranging from $135 million to $140 million, revenue from sales of Captisol ranging from $35 million to $40 million and contract revenue ranging from $10 million to $20 million. These revenue components result in a total revenue forecast of $180 million to $200 million. Ligand notes that with total revenue of $180 million to $200 million, adjusted earnings per diluted share2 are anticipated to range from approximately $6.00 to $6.25.

Guidance

LGND

Ligand Pharmaceuticals Reaffirms FY2025 Outlook: Adj EPS of $6.00-$6.25 vs $6.15 Estimate; Sales of $180.00M-$200.00M vs $187.75M Estimate

ADT Sees FY25 Revenue $5.025B-$5.225B Vs $5.098B Estimate; Sees Adj. EPS $0.77-$0.85 Vs $0.81 Estimate

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.54) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is a 86.49 percent decrease over sales of $37.00 thousand the same period last year.

Altimmune Q4 2024 GAAP EPS $(0.33), Inline, Sales $5.00K Down From $37.00K YoY, Cash, Cash Equivalents And Short-term Investments Of $131.9M

CCOI

Cogent Comms Hldgs Q4 2024 GAAP EPS $(0.91) Beats $(1.20) Estimate, Sales $252.291M Miss $258.232M Estimate

PZZA

Papa John's Sees FY25 System-Wide Sales Up 2%-5%, Sees FY25 Adjusted EBITDA $200M-$220M, Sees FY25 North America Gross Restaurant Openings 85-115, International 180-200

JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $2.37 by 10.13 percent. This is a 5.24 percent increase over earnings of $2.48 per share from the same period last year. The company reported quarterly sales of $2.19 billion which missed the analyst consensus estimate of $2.22 billion by 1.53 percent. This is a 1.93 percent decrease over sales of $2.23 billion the same period last year.

Comments

Black Swan Graphene

Black Swan Graphene (BSWGD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga